The agency won a three-way pitch to secure the account (PRWeek, 8 October) – and will also promote Wyeth’s long-established injectable penicillin Tazocin.
Tygacil may represent a major advance in the treatment of serious hospital-based infections including ‘superbug’ MRSA.
The product, one of a crop of drugs unveiled to investment analysts in the US earlier this year, is currently in phase III clinical trials.
Ketchum scooped a PR contract to promote Tygacil globally in a pitch process held at Wyeth’s global HQ in Pennsylvania four months ago (PRWeek, 25 June).
The campaign for Tygacil will involve the promotion of yet-to-be-published data on the product’s efficacy.
